Pharmadrug Inc.

PHRX

CA71716W2040

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 02:08:18 2024-04-23 pm EDT			5-day change	1st Jan Change
0.03 ^CAD	0.00%		-14.29%	-45.45%

Apr. 16	PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	MT
Mar. 13	Pharmadrug's SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine	CI

Pharmadrug Inc. will Change its Ticker to PHRX from BUZZ

August 03, 2021 at 12:00 am EDT

Effective August 03, 2021, Pharmadrug Inc. will change its Canadian National Stock Exchange stock ticker symbol to PHRX from BUZZ.

Latest news about Pharmadrug Inc.

PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	Apr. 16	MT
Pharmadrug's SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine	Mar. 13	CI
PharmaDrug Inc Announces Board Changes	Feb. 27	CI
PharmaTher Provides Update For PD-001	Feb. 21	MT
Pharmadrug Inc. Announces Marketing and Distribution Services Agreement with Outside the Box Capital Inc	Feb. 12	CI
Pharmadrug Inc. announced that it has received CAD 0.326 million in funding	Feb. 07	CI
Pharmadrug Inc. announced that it expects to receive CAD 0.326 million in funding	Jan. 31	CI
Pharmadrug Inc. completed the acquisition of Securedose Synthetics Inc.	Nov. 06	CI
Pharmadrug Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-29	CI
Pharmadrug Inc. entered into a definitive agreement to acquire Securedose Synthetics Inc. for CAD 1.1 million.	23-10-26	CI
Pharmadrug Inc. Announces CFO Changes	23-10-20	CI
PharmaDrug Inc. Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease	23-09-14	CI
PharmaDrug Inc. Announces Board Changes	23-09-06	CI
PharmaDrug Inc. Announces CEO Changes	23-09-06	CI
Pharmadrug Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Pharmadrug Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Pharmadrug Inc. Appoints David Posner to Its Advisory Committee and as Consultant	23-05-23	CI
Pharmadrug Inc. Auditor Raises 'Going Concern' Doubt	23-05-11	CI
Pharmadrug Inc. announced that it has received CAD 0.1 million in funding	23-04-13	CI
PharmaDrug Inc. Enters into Research Collaboration Agreement with PharmaTher Holdings Ltd	23-02-22	CI
PharmaDrug Inc. Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer	23-02-13	CI
PharmaDrug Advances Programs in Oncology with Filing of Patent Cooperation Treaty Application Detailing the Use of PD-001 for Treatment of Prostate Cancer	23-01-31	CI
Pharmadrug Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
PharmaDrug Inc. Advances Programs in Oncology and Infectious Disease Through Completion of cGMP Drug Substance Manufacturing	22-10-04	CI
Pharmadrug Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-29	CI

PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Companyâs subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
PHARMADRUG INC.	-45.45%	2.29M
MCKESSON CORPORATION	+14.88%	69.91B
SINOPHARM GROUP CO. LTD.	+5.62%	8.32B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+5.20%	8.07B
HUADONG MEDICINE CO., LTD	-20.43%	7.97B
H. LUNDBECK A/S	+0.73%	4.56B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+16.98%	4.31B
EBOS GROUP LIMITED	-2.00%	3.99B
GALENICA AG	-2.89%	3.87B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+21.87%	3.63B